Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Hybrigenics SA (ALHYG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10162
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cancer, chronic lymphocytic leukaemia and moderate to severe psoriasis. The company is also investigating the action of deubiquitinating enzymes (DUB) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics’ employs its expertise in DUBs to discover and develop new treatments. It also offers specialized scientific services for validating and inhibiting protein interactions in animal, plant or microbiological cells. Hybrigenics is headquartered in Paris, France.

Hybrigenics SA (ALHYG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Hybrigenics Acquires Genomic Division Of Imaxio 11
Equity Offering 12
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For US$8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For US$4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For US$1.9 Million 19
Hybrigenics SA – Key Competitors 20
Hybrigenics SA – Key Employees 21
Hybrigenics SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Apr 26, 2018: Hybrigenics Announces Its Full Year 2017 Results 23
Apr 28, 2017: Hybrigenics fuLL year 2016 resuLts 24
Product News 25
03/26/2018: Hybrigenics broad spectrum inhibitor of Ubiquitin-Specific Proteases shows antiviral activity against human adenoviruses 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Hybrigenics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics Acquires Genomic Division Of Imaxio 11
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For US$8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For US$4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For US$1.9 Million 19
Hybrigenics SA, Key Competitors 20
Hybrigenics SA, Key Employees 21
Hybrigenics SA, Subsidiaries 22

List of Figures
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Oilfield Services Ltd (2883):石油・ガス:M&Aディール及び事業提携情報
    Summary China Oilfield Services Ltd (COSL) is an integrated oilfield services company. Its services cover each phase of offshore oil and gas exploration, development and production. Its products portfolio includes logging and perforation equipment, oilfield chemicals, well completion tools, sand con …
  • Alamos Gold Inc:企業の戦略・SWOT・財務分析
    Alamos Gold Inc - Strategy, SWOT and Corporate Finance Report Summary Alamos Gold Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Edwards Lifesciences Corp (EW):企業の財務・戦略的SWOT分析
    Edwards Lifesciences Corp (EW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Graphic Packaging Holding Company:戦略・SWOT・企業財務分析
    Graphic Packaging Holding Company - Strategy, SWOT and Corporate Finance Report Summary Graphic Packaging Holding Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Japan Airlines Co Ltd:企業のM&A・事業提携・投資動向
    Japan Airlines Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Japan Airlines Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Targovax ASA (TRVX):製薬・医療:M&Aディール及び事業提携情報
    Summary Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline …
  • Takara Holdings Inc (2531):企業の財務・戦略的SWOT分析
    Takara Holdings Inc (2531) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • McEwen Mining Inc.:企業の戦略・SWOT・財務情報
    McEwen Mining Inc. - Strategy, SWOT and Corporate Finance Report Summary McEwen Mining Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Ding He Mining Holdings Ltd:企業のM&A・事業提携・投資動向
    Ding He Mining Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ding He Mining Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Jiangsu Expressway Co Ltd (600377):企業の財務・戦略的SWOT分析
    Summary Jiangsu Expressway Co Ltd (Jiangsu Expressway) is a highway development company that offers services in investment, construction, operation and management of toll expressways within Jiangsu province. The company offers services such as geographical services, service area development, express …
  • The Jim Pattison Group:企業の戦略・SWOT・財務情報
    The Jim Pattison Group - Strategy, SWOT and Corporate Finance Report Summary The Jim Pattison Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Actinogen Medical Ltd (ACW):企業の財務・戦略的SWOT分析
    Summary Actinogen Medical Ltd (Actinogen), formerly Actinogen Ltd is a biotechnology company that develops novel treatments for alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases. The company’s xanamem is a novel drug under development for …
  • Tourmaline Oil Corp.:企業のM&A・事業提携・投資動向
    Tourmaline Oil Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tourmaline Oil Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Biohaven Pharmaceutical Holding Company Ltd (BHVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that include …
  • Choice Spine LLC:製品パイプライン分析
    Summary Choice Spine LLC (Choice Spine) is a spinal implant company that develops, manufactures and markets surgeon focused systems. The company offers products which include cervical and thoracolumbar systems. Its cervical systems comprise plate systems, inter-body systems and fixation systems. Cho …
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • NovoCure Ltd (NVCR)-医療機器分野:企業M&A・提携分析
    Summary NovoCure Ltd (NovoCure) is an drug company that concentrates on the development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in various types of cancer indications such as ovarian cancer, malignant melanoma, hepatocellul …
  • Bio-Rad Laboratories Inc (BIO):企業の財務・戦略的SWOT分析
    Bio-Rad Laboratories Inc (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • CRH Medical Corp (CRH):企業の財務・戦略的SWOT分析
    Summary CRH Medical Corp (CRH Medical), is a medical device company that offers treatment of hemorrhoids. The company provides CRH O’Regan System, a hemorrhoid technology for treating hemorrhoid. It offers topical ointments and creams including preparation H for the treatment of hemorrhoid. CRH Medi …
  • Sadbhav Engineering Ltd:企業の戦略・SWOT・財務情報
    Sadbhav Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Sadbhav Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆